Medical Market Report

Global Clinical Oncology Next Generation Sequencing (NGS) Market By Type (NGS Pre-Sequencing, Sequencing, NGS Data Analysis, and Primary, Secondary & Tertiary Data Analysis), By Application (Academic & Clinical Research, Hospitals & Clinics, and Pharma & Biotech Entities), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • 138350
  • 18-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    Global Clinical Oncology Next Generation Sequencing (NGS) Market is estimated to be valued US$ XX.X million in 2019. The report on Clinical Oncology Next Generation Sequencing (NGS) Market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, etc. for the forecast year up to 2029. The global clinical oncology next generation sequencing (ngs) market is segmented on the basis of Type, Application, and geography.

    Europe market was valued at US$ XX.X million in 2018 and is projected to reach US$ XX.X million in 2029, and register a CAGR of X.X% during the forecast period, according to a new Market.us (Prudour Research) study.

    Clinical Oncology Next Generation Sequencing (NGS) Market Scope:

    By type, the market is segmented into NGS Pre-Sequencing, Sequencing, NGS Data Analysis, and Primary, Secondary & Tertiary Data Analysis. By Application, the market is divided into Academic & Clinical Research, Hospitals & Clinics, and Pharma & Biotech Entities.
    Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include Illumina, Roche, Agilent Technologies, Knome, Genomatix Software, GATC Biotech, Oxford Nanopore Technologies, Macrogen, Life Technologies, DNASTAR, Exosome Diagnostics, Biomatters, CLC Bio, BGI, Qiagen, Perkin Elmer, Pacific Bioscience, Partek, GnuBIO, and Foundation Medicine.

    Key Market Segments

    Type

    NGS Pre-Sequencing

    Sequencing

    NGS Data Analysis

    Primary, Secondary & Tertiary Data Analysis

    Application

    Academic & Clinical Research

    Hospitals & Clinics

    Pharma & Biotech Entities

    Key Market Players included in the report:

    Illumina

    Roche

    Agilent Technologies

    Knome

    Genomatix Software

    GATC Biotech

    Oxford Nanopore Technologies

    Macrogen

    Life Technologies

    DNASTAR

    Exosome Diagnostics

    Biomatters

    CLC Bio

    BGI

    Qiagen

    Perkin Elmer

    Pacific Bioscience

    Partek

    GnuBIO

    Foundation Medicine

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and Clinical Oncology Next Generation Sequencing (NGS) Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Clinical Oncology Next Generation Sequencing (NGS) Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers Clinical Oncology Next Generation Sequencing (NGS) Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Clinical Oncology Next Generation Sequencing (NGS) Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the Clinical Oncology Next Generation Sequencing (NGS) Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the Clinical Oncology Next Generation Sequencing (NGS) Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of Clinical Oncology Next Generation Sequencing (NGS) sub-markets, depending on key regions (various vital states).
    To analyze Clinical Oncology Next Generation Sequencing (NGS) Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the Clinical Oncology Next Generation Sequencing (NGS) Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2013 to 2018, and also prediction to 2029.
    Primary worldwide Clinical Oncology Next Generation Sequencing (NGS) Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. Clinical Oncology Next Generation Sequencing (NGS) Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope
    

    2. Executive Summary
    

      2.1. Key Findings by Major Segments
    
  2.2. Top strategies by Major Players
    

    3. Global Clinical Oncology Next Generation Sequencing (NGS) Market Overview
    

    3.1. Clinical Oncology Next Generation Sequencing (NGS) Market Dynamics
    

        3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges
    

      3.2. PESTLE Analysis
    
  3.3. Opportunity Map Analysis
    
  3.4. PORTER’S Five Forces Analysis
    
  3.5. Market Competition Scenario Analysis
    
  3.6. Product Life Cycle Analysis
    
  3.7. Opportunity Orbits
    
  3.8. Production Analysis by Region/Company
    
  3.9. Industry chain Analysis
    
  3.10. Marketing Strategy
    

    4. Global Clinical Oncology Next Generation Sequencing (NGS) Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

      4.1. Global Clinical Oncology Next Generation Sequencing (NGS) Market Analysis by Type: Introduction
    
  4.2. Market Size and Forecast by Region
    
  4.3. NGS Pre-Sequencing
    

      4.4. Sequencing
    

      4.5. NGS Data Analysis
    

      4.6. Primary, Secondary & Tertiary Data Analysis
    

    5. Global Clinical Oncology Next Generation Sequencing (NGS) Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

      5.1. Global Clinical Oncology Next Generation Sequencing (NGS) Market Analysis by Application: Introduction
    
  5.2. Market Size and Forecast by Region
    
  5.3. Academic & Clinical Research
    

      5.4. Hospitals & Clinics
    

      5.5. Pharma & Biotech Entities
    

    6. Global Clinical Oncology Next Generation Sequencing (NGS) Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

      6.1. North America
    

        6.1.1. North America Clinical Oncology Next Generation Sequencing (NGS) Market: Regional Trend Analysis
    

         6.1.1.1. US
    
     6.1.1.2. Canada
    
     6.1.1.3. Mexico
    

      6.2.1. Europe
    

        6.2.1. Europe Clinical Oncology Next Generation Sequencing (NGS) Market: Regional Trend Analysis
    

         6.2.1.1. Germany
    
     6.2.1.2. France
    
     6.2.1.3. UK
    
     6.2.1.4. Russia
    
     6.2.1.5. Italy
    
     6.2.1.6. Spain
    
     6.2.1.7. Rest of Europe
    

      6.3. Asia-Pacific
    

        6.3.1. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market: Regional Trend Analysis
    

         6.3.1.1. China
    
     6.3.1.2. Japan
    
     6.3.1.3. Korea
    
     6.3.1.4. India
    
     6.3.1.5. Rest of Asia-Pacific
    

      6.4. Latin America
    

        6.4.1. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market: Regional Trend Analysis
    

         6.4.1.1. Brazil
    
     6.4.1.2. Argentina
    
     6.4.1.3. Rest of Latin America
    

      6.5. Middle East and Africa
    

        6.5.1. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market: Regional Trend Analysis
    

         6.5.1.1. GCC
    
     6.5.1.2. South Africa
    
     6.5.1.3. Israel
    
     6.5.1.4. Rest of MEA
    

    7. Global Clinical Oncology Next Generation Sequencing (NGS) Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

      7.1. Market Share Analysis
    
  7.2. Company Profiles
    
  7.3. Illumina
    

        7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments
    

      7.4. Roche
    

        7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments
    

      7.5. Agilent Technologies
    

        7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments
    

      7.6. Knome
    

        7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments
    

      7.7. Genomatix Software
    

        7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments
    

      7.8. GATC Biotech
    

        7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments
    

      7.9. Oxford Nanopore Technologies
    

        7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments
    

      7.10. Macrogen
    

        7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments
    

      7.11. Life Technologies
    

        7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments
    

      7.12. DNASTAR
    

        7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments
    

      7.13. Exosome Diagnostics
    

        7.13.1. Company Overview
    
    7.13.2. Financial Highlights
    
    7.13.3. Product Portfolio
    
    7.13.4. SWOT Analysis
    
    7.13.5. Key Strategies and Developments
    

      7.14. Biomatters
    

        7.14.1. Company Overview
    
    7.14.2. Financial Highlights
    
    7.14.3. Product Portfolio
    
    7.14.4. SWOT Analysis
    
    7.14.5. Key Strategies and Developments
    

      7.15. CLC Bio
    

        7.15.1. Company Overview
    
    7.15.2. Financial Highlights
    
    7.15.3. Product Portfolio
    
    7.15.4. SWOT Analysis
    
    7.15.5. Key Strategies and Developments
    

      7.16. BGI
    

        7.16.1. Company Overview
    
    7.16.2. Financial Highlights
    
    7.16.3. Product Portfolio
    
    7.16.4. SWOT Analysis
    
    7.16.5. Key Strategies and Developments
    

      7.17. Qiagen
    

        7.17.1. Company Overview
    
    7.17.2. Financial Highlights
    
    7.17.3. Product Portfolio
    
    7.17.4. SWOT Analysis
    
    7.17.5. Key Strategies and Developments
    

      7.18. Perkin Elmer
    

        7.18.1. Company Overview
    
    7.18.2. Financial Highlights
    
    7.18.3. Product Portfolio
    
    7.18.4. SWOT Analysis
    
    7.18.5. Key Strategies and Developments
    

      7.19. Pacific Bioscience
    

        7.19.1. Company Overview
    
    7.19.2. Financial Highlights
    
    7.19.3. Product Portfolio
    
    7.19.4. SWOT Analysis
    
    7.19.5. Key Strategies and Developments
    

      7.20. Partek
    

        7.20.1. Company Overview
    
    7.20.2. Financial Highlights
    
    7.20.3. Product Portfolio
    
    7.20.4. SWOT Analysis
    
    7.20.5. Key Strategies and Developments
    

      7.21. GnuBIO
    

        7.21.1. Company Overview
    
    7.21.2. Financial Highlights
    
    7.21.3. Product Portfolio
    
    7.21.4. SWOT Analysis
    
    7.21.5. Key Strategies and Developments
    

      7.22. Foundation Medicine
    

        7.22.1. Company Overview
    
    7.22.2. Financial Highlights
    
    7.22.3. Product Portfolio
    
    7.22.4. SWOT Analysis
    
    7.22.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.